Insys Therapeutics, a pharmaceutical company, has filed for Chapter 11 bankruptcy protection, less than a week after pleading guilty to federal fraud charges and agreeing to pay $225 million to resolve allegations tied to its addictive opioid painkiller. The bankruptcy filing is the first for a drug company accused of helping to fuel the opioid epidemic.